U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies by Smith, MA, Choudhary, GS, Pellagatti, A, Choi, K, Bolanos, LC, Bhagat, TD, Gordon-Mitchell, S, Von Ahrens, D, Pradhan, K, Steeples, V, Kim, S, Steidl, U, Walter, M, Fraser, IDC, Kulkarni, A, Salomonis, N, Komurov, K, Boultwood, J, Verma, A, Starczynowski, DT

Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations by Choudhary, GS, Pellagatti, A, Agianian, B, Smith, MA, Bhagat, TD, Gordon-Mitchell, S, Sahu, S, Pandey, S, Shah, N, Aluri, S, Aggarwal, R, Aminov, S, Schwartz, L, Steeples, V, Booher, RN, Ramachandra, M, Samson, M, Carbajal, M, Pradhan, K, Bowman, TV, Pillai, MM, Will, B, Wickrema, A, Shastri, A, Bradley, RK, Martell, RE, Steidl, UG, Gavathiotis, E, Boultwood, J, Starczynowski, DT, Verma, A

Wnt/ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome by Bhagat, T, Chen, S, Bartenstein, M, Barlowe, TS, von Ahrens, D, Choudhary, GS, Tivnan, P, Amin, E, Marcondes, AM, Sanders, MA, Hoogenboezem, RM, Kambhampati, S, Ramachandra, N, Mantzaris, I, Sukrithan, V, Laurence, R, Lopez, R, Bhagat, P, Giricz, O, Sohal, D, Wickrema, A, Yeung, CC, Gritsman, K, Aplan, PD, Hochedlinger, K, Yu, Y, Pradhan, K, Zhang, J, Greally, J, Mukherjee, S, Pellagatti, A, Boultwood, J, Will, B, Steidl, U, Raaijmakers, MH, Deeg, HJ, Kharas, MG, Verma, A